Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Chief Financial Officer | May 17, 2021 | May 19, 2021 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Senior Vice-President & CFO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date May 17, 2021 · Filed May 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,509 |
Reported balance
After 2021-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-17 · Exercise / conversion · Acquired 583 · Balance 1,509 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 584 |
Reported balance
After 2021-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-17 · Exercise / conversion · Disposed 583 · Balance 584 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019.
F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis.
F3: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,733 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 1,250 · Balance 9,733 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 9,129 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 604 · Balance 9,129 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 1,250 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 21:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000015 · wk-form4_1786741773.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. F3 · derivative.expiration_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 604 | $46.57 | $28,128.28 |
DisclosureSEC source: 0001194020-26-000015 · wk-form4_1786741773.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,129 F2 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000015 · wk-form4_1786741773.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000013 · wk-form4_1785531954.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed F1 · derivative.exercise_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. F1 · derivative.expiration_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000010 · wk-form4_1773173570.xml · derivative · entry 6 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000010 · wk-form4_1773173570.xml · derivative · entry 5 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,450 | $54.73 | $79,358.50 |
DisclosureSEC source: 0001194020-26-000010 · wk-form4_1773173570.xml · nonDerivative · entry 4 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,232 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000010 · wk-form4_1773173570.xml · nonDerivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,433 | $54.73 | $78,428.09 |
DisclosureSEC source: 0001194020-26-000010 · wk-form4_1773173570.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,682 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000010 · wk-form4_1773173570.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000008 · wk-form4_1772572265.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000008 · wk-form4_1772572265.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000006 · wk-form4_1772140756.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,279 | $50.69 | $64,832.51 |
DisclosureSEC source: 0001194020-26-000006 · wk-form4_1772140756.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,115 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000006 · wk-form4_1772140756.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,394 Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · derivative · entry 9 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F5 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · derivative · entry 8 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · derivative · entry 7 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,375 Underlying: Common Stock · 1,125 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,524 | $50.86 | $77,510.64 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · nonDerivative · entry 6 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,894 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · nonDerivative · entry 5 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,418 Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 242 | $50.86 | $12,308.12 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · nonDerivative · entry 4 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,418 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · nonDerivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,660 Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 603 | $51.35 | $30,964.05 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,160 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000004 · wk-form4_1772058117.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,763 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001194020-26-000002 · wk-form4_1771624144.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001194020-26-000002 · wk-form4_1771624144.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-02-18 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 18, 2027. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 11,780 | $44.49 | $524,092.20 |
DisclosureSEC source: 0001194020-25-000004 · wk-form4_1756239508.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,246 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.66, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011984 · wk-form4_1741724133.xml · derivative · entry 6 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F5 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011984 · wk-form4_1741724133.xml · derivative · entry 5 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F4 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 955 | $32.06 | $30,617.30 |
DisclosureSEC source: 0001628280-25-011984 · wk-form4_1741724133.xml · nonDerivative · entry 4 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,681 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011984 · wk-form4_1741724133.xml · nonDerivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,062 | $32.06 | $34,047.72 |
DisclosureSEC source: 0001628280-25-011984 · wk-form4_1741724133.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,836 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:15 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011984 · wk-form4_1741724133.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,330 | $33.05 | $43,956.50 |
DisclosureSEC source: 0001628280-25-010487 · wk-form4_1741209786.xml · nonDerivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,898 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,587 | $33.05 | $52,450.35 |
DisclosureSEC source: 0001628280-25-010487 · wk-form4_1741209786.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,228 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:23 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 276 | $33.05 | $9,121.80 |
DisclosureSEC source: 0001628280-25-010487 · wk-form4_1741209786.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,815 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:20 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009869 · wk-form4_1741123193.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:20 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009869 · wk-form4_1741123193.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 01:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007526 · wk-form4_1740446208.xml · derivative · entry 6 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 01:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007526 · wk-form4_1740446208.xml · nonDerivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,091 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007526 · wk-form4_1740446208.xml · derivative · entry 5 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007526 · wk-form4_1740446208.xml · derivative · entry 4 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007526 · wk-form4_1740446208.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,591 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007526 · wk-form4_1740446208.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,591 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007156 · wk-form4_1740174196.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007156 · wk-form4_1740174196.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2026. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028273 · tm247055-22_4seq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,314 | $29.06 | $38,184.84 |
DisclosureSEC source: 0001104659-24-028273 · tm247055-22_4seq1.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,190 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028273 · tm247055-22_4seq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,504 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027567 · tm247055-3_4seq1.xml · derivative · entry 4 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-02-22 F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.